30 terminated. 30 Phase 1, 7 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 30 | Terminated 30 |
| Phase 2 | 7 | Terminated 7 |
Follow Oligodendroglioma: new trials by email Literature Review of Oligodendroglioma trials Research Report on Oligodendroglioma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Studying the Safety, Efficacy, and Pharmacokinetic Characteristics of BNCT in Patients With Recurrent High-grade Gliomas 500mg/kg/3hr followed by neutron irradiation to reach maximum brain dose of 9Gy-Eq, 500mg/kg/3hr followed by neutron irradiation to reach maximum brain dose of 11Gy-Eq, 500mg/kg/3hr followed by neutron irradiation to reach maximum brain dose of 13Gy-Eq - Recurrent High-grade Glioma, Recurrent Glioblastoma | Phase 1 / Phase 2 | Terminated | Dawonmedax Co., Ltd. | 7 | 2022-12-05 | 2025-02-21 |
| Determining Dose of Regadenoson Most Likely to Transiently Alter the Integrity of the Blood-Brain Barrier in Patients With High Grade Gliomas Regadenoson 0.05mg, Regadensoson 0.1mg, Regadensoson 0.2mg - High Grade Glioma, Anaplastic Astrocytoma | Phase 1 | Terminated | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 7 | 2019-12-06 | 2023-10-06 |
| A Study of Varlilumab and IMA950 Vaccine Plus Poly-ICLC in Patients With WHO Grade II Low-Grade Glioma (LGG) IMA950, poly-ICLC, Varlilumab - Glioma, Malignant Glioma | Phase 1 | Terminated | Nicholas Butowski | 14 | 2017-04-03 | 2024-06-14 |
| First in Patient Study for PF-06840003 in Malignant Gliomas PF-06840003 - Oligodendroglioma, Astrocytoma | Phase 1 | Terminated | Pfizer | 17 | 2016-09-09 | 2020-01-27 |
| Palbociclib Isethionate in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors palbociclib isethionate, pharmacological study, laboratory biomarker analysis - Childhood Choroid Plexus Tumor, Childhood Ependymoblastoma | Phase 1 | Terminated | Pediatric Brain Tumor Consortium | 35 | 2014-12-08 | 2021-03-02 |
| Temozolomide and Ascorbic Acid in Treating Patients With Recurrent High-Grade Glioma ascorbic acid, temozolomide, quality-of-life assessment - Anaplastic Astrocytoma, Anaplastic Oligodendroglioma | Phase 1 | Terminated | University of Nebraska | 4 | 2014-06-16 | 2023-11-24 |
| Oncolytic HSV-1716 in Treating Younger Patients With Refractory or Recurrent High Grade Glioma That Can Be Removed By Surgery oncolytic HSV-1716, dexamethasone, therapeutic conventional surgery - Recurrent Childhood Anaplastic Astrocytoma, Recurrent Childhood Anaplastic Oligoastrocytoma | Phase 1 | Terminated | Pediatric Brain Tumor Consortium | 2 | 2013-12-01 | 2016-05-30 |
| Intraarterial Infusion Of Erbitux and Bevacizumab For Relapsed/Refractory Intracranial Glioma In Patients Under 22 SIACI of Erbitux and Bevacizumab - Glioblastoma Multiforme, Fibrillary Astrocytoma of Brain | Phase 1 / Phase 2 | Terminated | Weill Medical College of Cornell University | 13 | 2013-06-01 | 2022-08-09 |
| Phase I/II Trial of AXL1717 in the Treatment of Recurrent Malignant Astrocytomas AXL1717 - Glioblastoma, Gliosarcoma | Phase 1 / Phase 2 | Terminated | Rush University Medical Center | 10 | 2012-12-01 | 2023-05-22 |
| High-Dose Vorinostat and Fractionated Stereotactic Body Radiation Therapy in Treating Patients With Recurrent Glioma Vorinostat, Stereotactic Radiosurgery, Laboratory Biomarker Analysis - Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma | Phase 1 | Terminated | National Cancer Institute (NCI) | 30 | 2012-06-01 | 2014-12-23 |
| Plerixafor (AMD3100) and Bevacizumab for Recurrent High-Grade Glioma Plerixafor, Bevacizumab, Surgery - High Grade Glioma: Glioblastoma (GBM), High Grade Glioma: Gliosarcoma | Phase 1 | Terminated | Patrick Y. Wen, MD | 26 | 2011-12-01 | 2017-11-17 |
| RO4929097 in Treating Patients With Recurrent Invasive Gliomas gamma-secretase/Notch signalling pathway inhibitor RO4929097, therapeutic conventional surgery, pharmacological study - Adult Anaplastic Oligodendroglioma, Adult Brain Stem Glioma | Phase 1 | Terminated | National Cancer Institute (NCI) | 22 | 2011-07-01 | 2013-02-07 |
| Phase I / II Vorinostat, Erlotinib and Temozolomide for Recurrent Glioblastoma Multiforme (GBM) Vorinostat, Erlotinib, Temozolomide - Brain Cancer, Glioblastoma Multiforme | Phase 1 / Phase 2 | Terminated | M.D. Anderson Cancer Center | 21 | 2011-06-01 | 2021-08-25 |
| A Continuation Protocol for Patients Previously Enrolled in a Study of Toca 511 Toca 511 vector, Toca FC • Flucytosine • 5-FC • 5-Fluorocytosine - Glioblastoma Multiforme, Astrocytoma | Phase 1 | Terminated | Tocagen Inc. | 65 | 2011-02-01 | 2020-03-30 |
| RO4929097and Bevacizumab in Treating Patients With Progressive or Recurrent Malignant Glioma gamma-secretase/Notch signalling pathway inhibitor RO4929097, bevacizumab, laboratory biomarker analysis - Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma | Phase 1 / Phase 2 | Terminated | National Cancer Institute (NCI) | 13 | 2010-12-01 | 2015-12-14 |
| Aminolevulinic Acid During Surgery in Treating Patients With Malignant Brain Tumors aminolevulinic acid, laboratory biomarker analysis, therapeutic conventional surgery - Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma | Phase 1 | Terminated | University of Washington | 6 | 2010-06-01 | 2017-02-15 |
| Erlotinib Hydrochloride and Isotretinoin in Treating Patients With Recurrent Malignant Glioma erlotinib hydrochloride, isotretinoin, laboratory biomarker analysis - Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma | Phase 1 | Terminated | Wake Forest University Health Sciences | 5 | 2010-05-01 | 2018-08-01 |
| Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia gamma-secretase/Notch signalling pathway inhibitor RO4929097, diagnostic laboratory biomarker analysis, pharmacological study - Childhood Atypical Teratoid/Rhabdoid Tumor, Childhood Central Nervous System Choriocarcinoma | Phase 1 | Terminated | National Cancer Institute (NCI) | 129 | 2010-03-01 | 2014-11-05 |
| Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors carboplatin, dasatinib, etoposide phosphate - Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor | Phase 1 / Phase 2 | Terminated | City of Hope Medical Center | 7 | 2008-09-10 | 2026-11-04 |
| MK0752 in Treating Young Patients With Recurrent or Refractory CNS Cancer MK-0752 - Brain and Central Nervous System Tumors | Phase 1 | Terminated | Pediatric Brain Tumor Consortium | 33 | 2008-07-01 | 2012-03-06 |
Showing 20 of 30. Sign in to see all of them.
Astrocytoma (29) · Glioblastoma (19) · Glioma (16) · Gliosarcoma (13) · Brain Neoplasms (10) · Central Nervous System Neoplasms (9) · Medulloblastoma (9) · Choroid Plexus Neoplasms (7) · Familial ependymoma (7) · Optic Nerve Glioma (6) · Burkitt Lymphoma (4) · Lymphoma (4) · Rhabdoid Tumor (4) · Dendritic Cell Sarcoma, Interdigitating (3)
Neoplasms (30) · Neoplasms by Histologic Type (30) · Neoplasms, Germ Cell and Embryonal (30) · Neoplasms, Glandular and Epithelial (30) · Neoplasms, Nerve Tissue (30) · Neuroectodermal Tumors (30) · Neoplasms, Neuroepithelial (28) · Neoplasms by Site (21) · Nervous System Diseases (21) · Nervous System Neoplasms (21) · Brain Diseases (18) · Central Nervous System Diseases (18) · Glioma (14) · Central Nervous System Neoplasms (12) · Brain Neoplasms (8)
Temozolomide (4) · 2,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide (3) · Bevacizumab (3) · Calcium Dobesilate (2) · Carboplatin (2) · Dexamethasone (2) · Erlotinib Hydrochloride (2) · Filgrastim (2) · Surgical Procedures, Operative (2) · Vorinostat (2) · etoposide phosphate (2) · 2-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole (1) · 3-(4-((4-chlorophenyl)sulfonyl)-4-(2,5-difluorophenyl)cyclohexyl)propanoic acid (1) · Acetylcysteine (1) · Aminolevulinic Acid (1)
National Cancer Institute (NCI) (6) · Pediatric Brain Tumor Consortium (6) · M.D. Anderson Cancer Center (2) · OHSU Knight Cancer Institute (2) · Case Comprehensive Cancer Center (1) · City of Hope Medical Center (1) · Dawonmedax Co., Ltd. (1) · Nicholas Butowski (1) · Northwestern University (1) · Patrick Y. Wen, MD (1) · Pfizer (1) · Rush University Medical Center (1) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (1) · Tocagen Inc. (1) · University of Nebraska (1)
United States (28) · Canada (2) · South Korea (1)
Edward A. Neuwelt, MD (2) · John DeGroot, MD (2) · Asha Das, MD (1) · Daniel Silbergeld (1) · David Van Mater, MD (1) · Edward Pan, MD (1) · Glenn Lesser (1) · Hideho Okada, MD, PhD (1) · Jeffery Greenfield, MD PhD (1) · Jeffrey Olson (1) · Jeffrey Raizer, MD (1) · Judith K. Sato, MD (1) · Mariko DeWire (1) · Mark W. Kieran, MD, PhD (1) · Maryam Fouladi, MD (1)
PMID 19065567, PMID 30232146, PMID 32436060, PMID 34359048, PMID 37553297, PMID 40225909
U01CA081457 (4), N01CM00032 (1), P30CA033572 (1), P30CA036727 (1), P30CA043703 (1), P30CA056036 (1), P30CA069533 (1), R21CA076192 (1), R21CA233856 (1), U01CA062475 (1), U01CA097452 (1), U01CA137443 (1), UM1CA137443 (1)